REGN Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own REGN shares is 1933, representing 90.73% of the company's common stock.

DIMENSIONAL FUND ADVISORS LP, in the last quarter, reduced its stake in REGN by -0.77% restricting it's holding to 588.95 thousand shares of worth nearly $566.86M. CAPITAL WORLD INVESTORS also lessened -9.27% of the REGN shares from its portfolio, reducing its holding to 4.65 million shares of worth $4.48B. LOOMIS SAYLES & CO L P also shunned REGN shares holding by -0.97% last quarter which brought its holding to 1.21 million shares worth $1.16B.

As per its latest 13F filing, CAPITAL INTERNATIONAL INVESTORS increased its stake in REGN by 7.31% in the last quarter. The institutional holder raised its holding to 3.13 million shares having worth more than $3.01B. GEODE CAPITAL MANAGEMENT, LLC also added 0.95% more shares of REGN to its portfolio, raising its holding to 2.38 million shares of worth $2.28B. FRANKLIN RESOURCES INC also increased its REGN shares holding by 249.98% which brought its holding to 1.69 million shares worth $1.63B.

The insider with the most stakes in REGN is YANCOPOULOS GEORGE , Bd. Co-Chair, President & CSO at the company. Additionally, REGN stock is highly held by EVP Research and Development STAHL NEIL and EVP Research MURPHY ANDREW J among others.

Company executives, directors, and other insiders own 1.57% percent of Regeneron Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 6 transaction(s) in which REGN insiders have sold stock, totaling 3.21K shares. Insiders that have sold shares include MCCOURT MARION, RYAN ARTHUR F, and FENIMORE CHRISTOPHER R..

There have been 0 transaction(s) during the past 6-months in which Regeneron Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 74.06K Regeneron Pharmaceuticals, Inc. shares are held by insiders, which represents about 1.57% of REGN stock.

REGN Bd. Co-Chair, President & CSO, YANCOPOULOS GEORGE holds the largest portfolio of the company's shares. REGN shares owned by YANCOPOULOS total nearly 786.38 thousand.

DIMENSIONAL FUND ADVISORS LP is the largest institutional owner in REGN which holds 588.95 thousand shares worth $566.86M or 0.55% of the total REGN shares outstanding followed by CAPITAL WORLD INVESTORS with ownership of 4.65 million shares representing 4.32% of the REGN ownership. CAPITAL INTERNATIONAL INVESTORS is the third largest stakeholder with 3.13 million shares or 2.9% of the ownership worth more than $3.01B.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the REGN is concerned, it is a stock which is optionable.

Number of REGN shares short is 2.19M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 107.51M shares of REGN are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, REGN has 103.00M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for REGN is 2.52.